Ifty Khan, BSc, MSc, PhD

Ifty Khan, BSc, MSc, PhD

Ifty Khan, BSc, MSc, PhD

Director, Modelling and Analytics

Dr. Khan has over 15 years of experience in clinical trials and economic evaluation across industry, academia and the regulatory setting. Dr Khan has provided expertise across the full drug development process covering almost every disease area, including devices. He has been an expert adviser at the European Medicines Level, held joint NICE/EMEA/MHRA discussions and has published over 60 publications, including 2 books (Economic Evaluation for Cancer Drugs, Chapman & Hall, 2019; Design & Analysis of Clinical Trials for Economic Evaluation and Reimbursement, 2015). Dr Khan has also held an associate professorship in statistical methodology at King’s College London and Oxford University.  He was also a senior Research fellow in Health Economic at Warwick working closely with the Evidence Review Group that evaluates HTA submissions.  

Work Experience

Prior to joining Parexel, Dr Khan has held senior positions at several pharmaceutical companies including Eisai, Eli Lilly, Mundipharma and Novartis. Dr Khan was also a Senior Statistical Assessor at the MHRA, a senior statistician at the CRUK Cancer Trials Centre and held several academic appointments.


Dr Khan holds a BSc (Hon) in Statistics, MSc Statistics, MSc in Health Economics, a Post Graduate Diploma in Mathematics from the University of Cambridge and a PhD in statistical Modelling for Economic Evaluation from University College London. Dr Khan is a statistical reviewer for several high impact journals in statistics and health economics. He also is on the steering committee for MRC Trials Methodology Research Partnership methodological advances in health economic met.

We are always available for a conversation.